Turn Late-Stage Trial Data Into Higher Asset Value
TrialLens™ analyzes patient-level clinical trial data to identify responder profiles, non-responder patterns, adverse-event risks, and commercially valuable subgroup signals
Reconcile SDTM, ADaM, patient-level, clinical, biomarker, and treatment data
Unify fragmented trial data into one analysis-ready foundation
Less manual wrangling, faster analysis, and a single source of truth for downstream clinical and asset decisions.
Detect the clinical, biomarker, baseline, and treatment-pattern signals
Reveal why some patients do not respond to therapy
Understand failure modes earlier, refine development strategy, and strengthen responder/non-responder evidence for investors, partners, and internal teams.
Identify the patient characteristics, treatment conditions, and baseline risk factors
Uncover what drives adverse events and side effects
Generate clearer safety narratives, support risk stratification, and improve confidence in regulatory, partnering, and clinical planning discussions.
Surface the combinations of demographic, clinical, and biomarker features
Identify the patient profiles most likely to benefit from therapy
Enable sharper patient stratification, support precision trial design, and increase the strategic value of your dataset before fundraising, BD, or licensing conversations.
Client Implementations
Real clinical-data intelligence systems — adapted to each asset, dataset, and development strategy.
Trusted by Industry Leaders:
Start with a free demo on your own data
See how the solution works in practice before committing to deployment or integration.
Get in touch with us.
We’re here to assist you.
